A phase IV post-marketing study of OFEV for the treatment of idiopathic pulmonary fibrosis (IPF)

Trial Profile

A phase IV post-marketing study of OFEV for the treatment of idiopathic pulmonary fibrosis (IPF)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Nov 2015 New trial record
    • 13 Nov 2015 According to a Boehringer Ingelheim media release, results from this study will be presented at the Pulmonary Fibrosis Foundation's PFF Summit 2015.
    • 13 Nov 2015 Results published in a Boehringer Ingelheim media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top